CG On­col­o­gy spot­lights on­colyt­ic virus com­bo da­ta ahead of full read­out due next year

CG On­col­o­gy has been qui­et­ly chug­ging along — on­ly giv­ing up­dates at se­quen­tial can­cer con­fer­ences ahead of a full read­out on its on­colyt­ic virus can­cer ther­a­py next year.

In its lat­est at SITC, the Irvine, CA-based biotech showed up with longer-term da­ta on its ther­a­py, CG0070, in com­bi­na­tion with Mer­ck’s Keytru­da. While the da­ta are still ear­ly, they sug­gest more dura­bil­i­ty where the biotech had ini­tial­ly turned heads on ef­fi­ca­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER